Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 16 · below the Ichimoku cloud · RSI 45 · MACD above its signal
| 9.53 | 52-week high | +50.39% |
| 7.67 | Previous month high | +20.98% |
| 6.70 | Previous week high | +5.68% |
| 6.69 | R3 (classic) | +5.55% |
| 6.55 | R2 (classic) | +3.36% |
| 6.45 | R1 (classic) | +1.68% |
| 6.41 | Previous day high | +1.18% |
| 6.34 | Price now | |
| 6.31 | Pivot | −0.50% |
| 6.20 | S1 (classic) | −2.18% |
| 6.17 | Previous day low | −2.68% |
| 6.06 | S2 (classic) | −4.36% |
| 6.05 | Previous week low | −4.57% |
| 5.96 | S3 (classic) | −6.05% |
| 5.95 | Previous month low | −6.15% |
| 4.73 | 52-week low | −25.39% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.2M | 0.00% | 174.20K | +71% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a AURA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 31, 2026 | Person JulieOfficer | Stock Award(Grant) at price 0.00 per share. | 107.6K | — |
| Aug 31, 2026 | Hopkins Janet JillOfficer | Stock Award(Grant) at price 0.00 per share. | 58.9K | — |
| Aug 31, 2026 | Elazzouzi Amy FOfficer | Stock Award(Grant) at price 0.00 per share. | 23.5K | — |
| Aug 31, 2026 | Abu-Absi SusanChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 134.5K | — |
| Aug 31, 2026 | Kratz EricaOfficer | Stock Award(Grant) at price 0.00 per share. | 100.9K | — |
| Jul 6, 2026 | Bender JeremyDirector | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Jun 30, 2026 | Kilroy ConorOfficer | Stock Award(Grant) at price 0.00 per share. | 14.9K | — |
| Jun 15, 2026 | Gibney Anthony S.Chief Financial Officer | Sale at price 6.42 per share. | 12.8K | $82.33K |
| Jun 10, 2026 | Srivastava SapnaDirector | Stock Award(Grant) at price 0.00 per share. | 15K | — |
| Jun 10, 2026 | Mattessich Antony CharlesDirector | Stock Award(Grant) at price 0.00 per share. | 15K | — |
| Jun 10, 2026 | Johnson David MichaelDirector | Stock Award(Grant) at price 0.00 per share. | 15K | — |
| Jun 10, 2026 | Bitetti Teresa MarieDirector | Stock Award(Grant) at price 0.00 per share. | 15K | — |
| May 18, 2026 | Holles Natalie CChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 1.15M | — |
| May 6, 2026 | Matrix Capital Management Company, LpBeneficial Owner of more than 10% of a Class of Security | Sale at price 8.20 per share. | 6.92M | $56.77M |
| Apr 15, 2026 | Kilroy ConorOfficer | Sale at price 7.02 per share. | 11.7K | $82.40K |
| Mar 1, 2026 | Gibney Anthony S.Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 71.2K | — |
| Mar 1, 2026 | Kilroy ConorOfficer | Stock Award(Grant) at price 0.00 per share. | 62.3K | — |
| Mar 1, 2026 | Plavsic MarkChief Technology Officer | Stock Award(Grant) at price 0.00 per share. | 62.3K | — |
| Mar 1, 2026 | Elisabet De Los PinosChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 166K | — |
| Mar 1, 2026 | Hopkins Janet JillOfficer | Stock Award(Grant) at price 0.00 per share. | 89.1K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.8 | 5.2 | 13.6 | 5.4 | 6.0 | -5.0 | -1.3 | 2.4 | -12.5 | 1.0 | +16.3% | ||
| 2025 | -4.5 | -4.6 | -21.8 | -0.5 | 0.5 | 6.8 | 10.1 | -9.1 | -1.3 | -0.8 | 7.7 | -17.4 | −33.7% |
| 2024 | -13.1 | 17.8 | -13.5 | -5.7 | -0.7 | 2.9 | 35.1 | -22.1 | 12.1 | 17.2 | -10.8 | -11.7 | −7.2% |
| 2023 | -0.9 | -4.0 | -7.1 | -2.6 | 25.2 | 9.1 | -3.6 | -12.8 | -13.6 | -9.0 | -1.7 | 10.5 | −15.6% |
| 2022 | 7.5 | -1.9 | 22.9 | -22.9 | 3.0 | -18.9 | 0.6 | -6.3 | 35.6 | -31.6 | 15.3 | -26.5 | −38.2% |
| 2021 | 17.8 | -2.6 | +14.7% |
Buy / hold / sell counts
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.